Cambria

Cambria is a biotechnology company that develops experimental longevity drugs, including one that mimics exercise.

Why it’s in the news: It is in the news for its experimental drug and as part of a broader trend of companies pulling back on AI investments.

Latest on Cambria

• Companies pull back on AI as weak workplace collaboration hurts results: CambrianEdge
• STAT+: Cambrian’s experimental longevity drug mimics exercise
• [via Microsoft]
• Wikidata: Microsoft — capital ownership — Cambria
• [via Microsoft Corporation]
• Wikidata: Microsoft Corporation — capital ownership — Cambria

Connections

6 entities linked to Cambria across the news graph.